Big‑Pharma Goes All‑In on China: New R&D Hubs, Factories, and $5 Billion in Investments

At the 10th China Medical Innovation and Investment Conference, industry leaders highlighted how China has become a powerhouse for new drug discovery. More than half of the INDs approved by the U.S. FDA in 2024 now originate from Chinese research, a trend that multinational drug makers can’t ignore. In response, giants such as Eli Lilly, Pfizer, Bayer, AstraZeneca and Medtronic announced fresh R&D centers and production facilities across the country. AstraZeneca is fast‑tracking a $2.5 billion investment to launch its sixth global R&D hub in Beijing, while Medtronic opened its first digital‑health innovation base in Shanghai. Boehringer Ingelheim and Eli Lilly are also pouring billions into local manufacturing and capacity upgrades for diabetes and obesity treatments. Beyond building labs, multinationals are snapping up Chinese drug assets at a record pace, with companies like Takeda and Pfizer leading high‑value acquisitions. The shift is clear: China is no longer just a market for selling finished products; it is now a critical source of early‑stage innovation, from discovery through to production. Public data backs this surge—China now accounts for 38% of the world’s first‑in‑class drug launches and hosts nearly 2,000 clinical trials a year, a five‑fold increase since 2015. The result is a more competitive, higher‑quality landscape where the best global talent and technology converge on Chinese soil.

Read more

David Medical’s Subsidiary Wins Official Clearance for Cutting‑Edge Smart Device

David Medical announced that its wholly‑owned subsidiary has received a formal medical‑device registration certificate for its latest product, marking a major milestone for the company and underscoring the rapid shift toward digital, intelligent, and precision‑focused health technologies. The newly approved device was one of the headline attractions at this year’s China International Import Expo (CIIE), where it joined a lineup that included an “intelligent eyeglass” capable of picking up sound cues and a next‑generation MRI scanner being tested in clinical trials for Elon Musk’s brain‑computer‑interface venture. The launch comes at a time when China’s aging population is driving unprecedented demand for advanced medical equipment, raising the bar for manufacturers who must now compete on both innovation and quality. Over the past decade, many multinational medical firms that once simply imported technology have evolved into key partners in China’s burgeoning health‑tech ecosystem, establishing world‑class R&D hubs that accelerate the country’s output of groundbreaking medical solutions. Yet challenges remain. Domestic contract‑development‑manufacturing organizations (CDMOs) face a “precision craftsmanship” dilemma: despite a trillion‑yuan market opportunity, few have achieved the scale and reputation of giants like WuXi AppTec. Meanwhile, AI‑driven therapies are gaining traction, promising new ways to treat diseases by targeting the heart of the problem. David Medical’s certification win signals that the industry is moving forward, blending cutting‑edge tech with the urgent needs of an aging society.

Read more

AI‑Powered Medical Devices Take Center Stage at China’s Import Expo – Global Makers Turn R&D Toward China

The 8th China International Import Expo (CIIE) kicked off in Shanghai on November 5, turning the spotlight on the latest medical‑device innovations driven by artificial intelligence. Major players such as Siemens Healthineers, Medtronic and Germany’s Karl Storz used the massive exhibition floor to showcase how AI is reshaping diagnosis and treatment for heart disease and cancer. Siemens unveiled a 1,000‑square‑meter booth – its biggest ever at CIIE – featuring a high‑resolution DSA angiography system that can spot tiny lesions in just 2.5 seconds and offers AI‑guided assistance for neuro, cardiac and oncologic procedures. Medtronic introduced an FDA‑approved ultra‑rigid guidewire, a world‑first product that promises safer, more predictable transcatheter aortic valve replacements, and hinted at a Chinese market launch. Karl Storz displayed locally‑made cold‑light sources and insufflation machines, along with simulated outpatient cystoscopy and hysteroscopy suites that illustrate how minimally invasive tools can turn complex surgeries into same‑day procedures. China’s aggressive “AI+” strategy is fueling rapid digital transformation in healthcare, encouraging multinational firms to shift research and development to the country. The expo’s showcase is expected to speed up the adoption of these AI‑enhanced devices across Chinese hospitals, supporting the nation’s growing demand for advanced, less invasive medical care.

Read more